Proteon Therapeutics announces presentation
The Waltham-based Proteon Therapeutics, a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, recently announced that company management will present at the Stifel 2018 Healthcare Conference in New York City, New York at 5 p.m. Nov. 13. A live audio webcast of the presentation can be accessed by visiting the Investor and media section of the company’s website at http://proteontherapeutics.com. A replay of the webcast will be archived on the Proteon website following the presentation.
Eloxx Pharmaceuticals reports financial results
The Waltham-based Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, recently reported its financial results for the three and nine months ended Sept. 30 and provided a business update. “We are very pleased that ELX-02 has been granted orphan drug designations from the European Medicines Agency for cystic fibrosis, and the Food and Drug Administration in the US for cystinosis, and we look forward to reporting top line data from our phase two clinical trials in both indications in 2019. New positive data recently presented at the North American Cystic Fibrosis Conference demonstrated that ELX-02 is the first read-through agent to show dose responsive increases in CFTR function that was found to correlate with CFTRmRNA elevations to levels at or above wild-type,” said Robert E. Ward, chairman and CEO of Eloxx Pharmaceuticals. “We are also advancing several new investigational product candidates from our library in IND enabling studies in rare inherited retinal diseases, and we are very pleased to announce our strategic broad partnership with the Foundation Fighting Blindness as we identify a lead candidate later this year to move into clinical development.”
Histogenics Corporation announces financial and operating results
The Waltham-based Histogenics Corporation, a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced its financial and operating results for the quarter ended Sept. 30. “We continue to focus on advancing NeoCart towards the potential submission of a Biologics License Application by the end of the first quarter of 2019 and have an extensive dialogue with the FDA covering all aspects of the NeoCart development program, including the clinical data and related statistics from the NeoCart phase 3 clinical trial,” said Adam Gridley, President and CEO of Histogenics. “We believe, based on our continued analysis of the totality of the data, that NeoCart, if approved, may offer patients a treatment alternative that provides a more rapid recovery from pain and return to daily activity than other options to treat damaged knee cartilage. We are also working closely with MEDINET, our development and commercialization partner in Japan, toward the goal of initiating the Japanese phase 3 clinical trial of NeoCart in 2019.”
MutualOne Charitable Foundation funds playground
The Framingham-based MutualOne Charitable Foundation has awarded $5,000 to support a new Hoops & Homework community playground on Interfaith Terrace. The existing Interfaith playground had been deemed unsafe, out of compliance and was off-limits as recreation space until improvements were made. According to Foundation Chairman Robert P. Lamprey, the MutualOne grant allowed the purchase of a set of swings for the children’s enjoyment at the new playground. The $5,000 grant to support the new Hoops & Homework playground was among awards totaling $61,840 in the foundation’s most recent round of funding.